Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs

By J. DiMasi, Lanna Feldman, A. Seckler, A. Wilson. Clinical pharmacology and therapy, 2010

832 citations recorded by the source corpus.

Subfields: Economics and Econometrics, Management of Technology and Innovation, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/54d92c3b651d732ce8917a522fa73f73b85ffb22

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. H. Levine
2. S. D. Jones
3. D. Ecker

Citations in the corpus

• The therapeutic monoclonal antibody market (2015, background): “entering Phase 2 human clinical trials in recent years will ultimately achieve market approval with an average time from the start of Phase 2 clinical trials to approval of » seven years.(5-7) Given the large number of monoclonal antibody candidates currently in development, we expect that the numbe”